GlassScriptPhysician profile
Laura Vazquez
NPI 1225229610
$4,604.07
in general payments reported to CMS, 2019-2025
32 companies · $999 in 2025
The $999 reported for 2025 was more than what 97% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $252 · 2020: $203 · 2021: $839 · 2022: $392 · 2023: $781 · 2024: $1,138 · 2025: $999.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,917.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,917.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $663.56 | 2023-2025 | Qelbree, Qelbree |
| Corium, LLC | $521.07 | 2021-2025 | Azstarys |
| Pfizer INC. | $386.29 | 2019-2024 | |
| Sanofi Pasteur INC. | $360.30 | 2020-2025 | |
| Alk-Abello, INC | $306.25 | 2023-2025 | Odactra, Grastek, Ragwitek |
| Sanofi-Aventis U.S. LLC | $262.64 | 2023-2025 | |
| Cranial Technologies, INC | $252.31 | 2019-2025 | Doc Band |
| Tris Pharma INC | $221.67 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $195.98 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $170.82 | 2019-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Glaxosmithkline, LLC. | $168.50 | 2019-2025 | Bexsero |
| Seqirus USA INC | $161.45 | 2021-2025 | Flucelvax, Flucelvax Quadrivalent |
| Vyne Pharmaceuticals INC. | $149.15 | 2021 | |
| Ironshore Pharmaceuticals INC. | $136.62 | 2022-2024 | |
| Adlon Therapeutics L.P. | $96.90 | 2020-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $66.41 | 2019-2021 | |
| Kaleo, INC. | $63.88 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $52.26 | 2023-2024 | Flumist Quadrivalent |
| Cipher Pharmaceuticals US LLC | $50.74 | 2025 | Natroba, Spinosad |
| Kowa Pharmaceuticals America, INC. | $46.11 | 2024-2025 | Zoryve |
| Abbvie INC. | $43.17 | 2021 | |
| Collegium Pharmaceutical, INC. | $40.54 | 2025 | Jornay Pm |
| Verrica Pharmaceuticals INC. | $24.06 | 2024 | Ycanth |
| Galderma Laboratories, L.P. | $23.21 | 2021 | |
| Biomarin Pharmaceutical INC. | $21.09 | 2025 | Voxzogo 1.2mg |
| Shire North American Group INC | $20.82 | 2019 | |
| Amneal Pharmaceuticals LLC | $20.60 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $19.29 | 2021 | |
| Phadia US INC. | $15.56 | 2021 | |
| Mission Pharmacal Company | $15.27 | 2019 | |
| Aytu Biopharma, INC. | $14.56 | 2024 | Karbinal |
| Aimmune Therapeutics, INC. | $12.99 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Vazquez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.